FDA limits use of COVID-19 monoclonal antibody treatment in 8 states - Just The News

The agency writes that "the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant."

The U.S. Food and Drug Administration is no longer authorizing the monoclonal antibody treatment sotrovimab in 10 states and territories due to questions about its effectiveness against the BA.2 Omic… [+1212 chars]

full article...